From First Feeds to Future Health

Course Description:

Early-life nutrition plays a critical role in shaping the developing gut microbiome, immune system, and long-term health trajectory of infants. The first months of life represent a dynamic period during which feeding practices influence microbial colonization, immune maturation, digestive function, metabolic processes, and gut-brain communication. Emerging evidence suggests that microbiome development during infancy may have lasting implications for immune-mediated conditions, infectious disease risk, and overall health across the lifespan. 

Breastfeeding remains the biological reference standard for infant nutrition and provides a complex matrix of nutrients and bioactive components that support growth and development. Human milk contains a diverse array of human milk oligosaccharides (HMOs), beneficial bacteria, metabolites, immune factors, and other bioactive compounds that help shape the infant gut microbiome and support immune development. Research continues to demonstrate that HMO composition varies among mothers and throughout lactation, reflecting the dynamic nature of human milk and its role in supporting infant health. 

Human milk oligosaccharides are among the most abundant bioactive components in human milk and have emerged as key contributors to microbiome and immune development. HMOs resist digestion in the upper gastrointestinal tract, reach the colon intact, and selectively support the growth of beneficial bacteria such as Bifidobacterium. In addition to their prebiotic effects, HMOs may influence gut barrier integrity, immune signaling pathways, microbial metabolite production, and host-microbe interactions that contribute to healthy development.

Clinical and translational research suggests that formulas supplemented with HMOs may support digestive tolerance, promote microbiome profiles that more closely resemble those of breastfed infants, and influence markers associated with immune and gastrointestinal health. Growing evidence also highlights connections among HMOs, microbiota-derived metabolites, immune function, and potentially broader health outcomes beyond infancy. Understanding the relationship between early feeding, microbiome development, and HMO science may help healthcare professionals apply evidence-based nutrition strategies that support infant health, immune resilience, and developmental outcomes.

This program was originally presented at the International Conference on Nutrition and Growth on 10 April 2026.

Course Objectives:

• Examine how early infant feeding influences gut microbiota and immune health.
• Discuss the latest research on clinical studies of infant formula with human milk oligosaccharides (HMOs).
• Review the benefits of HMOs in infant health and beyond infancy.

Key Takeaways:

• The first months of life represent a critical window for gut microbiome development. Early feeding patterns influence microbial colonization, which may affect immune maturation, digestive function, metabolism, and health outcomes later in life. 
• Human milk oligosaccharides (HMOs) are among the most abundant bioactive components in human milk and selectively support beneficial gut bacteria. Beyond their prebiotic activity, HMOs may influence immune signaling, gut barrier function, and interactions between the microbiome and host physiology. 
• Human milk composition varies among mothers and throughout lactation. Factors such as maternal genetics, secretor status, stage of lactation, and environmental influences contribute to differences in HMO profiles that may affect infant microbiome and immune development.
• Preclinical and clinical research suggests that formulas supplemented with HMOs may support digestive tolerance, promote gut microbiome characteristics more similar to those observed in breastfed infants, and influence biomarkers associated with gastrointestinal and immune health.

Related Questions:

• Why is infant gut microbiome important for long-term health?
  The infant gut microbiome helps support digestion, nutrient metabolism, immune system development, and gut barrier function during a critical period of growth. Research suggests that early microbial colonization may influence immune maturation and help shape responses to environmental exposures throughout childhood. Disruptions in microbiome development during infancy have been associated with increased risk for infectious, allergies, and other immune-mediated conditions.
  
• How does breastfeeding affect gut microbiota development in infants?
  Breastfeeding is associated with the development of a microbiome enriched in beneficial bacteria, particularly Bifidobacterium species. Human milk provides a combination of nutrients, human milk oligosaccharides (HMOs), bacteria, metabolites, and immune factors that help shape microbial colonization during early life. These interactions contribute to digestive function, immune development, and the establishment of a healthy gastrointestinal environment.
• What are human milk oligosaccharides (HMOs), and what role do they play in infant health?
  Human milk oligosaccharides are complex bioactive carbohydrates naturally found in human milk and are among its most abundant solid components. Because HMOs resist digestion in the upper gastrointestinal tract, they reach the colon where they selectively nourish beneficial bacteria and influence microbial metabolite production. Evidence also suggests that HMOs may support immune function, gut barrier integrity, and communication between the microbiome and the developing host.
• Can HMO-containing infant formulas influence microbiome and immune outcomes?
  Clinical studies have shown that infant formulas supplemented with specific HMOs can promote microbiome characteristics that more closely resemble those observed in breastfed infants, including increased abundance of beneficial bacterial groups such as Bifidobacterium. Research has also demonstrated improvements in digestive tolerance and changes in biomarkers associated with gastrointestinal and immune function, including indicators of gut barrier integrity, immune activity, and microbiota-derived metabolites. While findings vary depending on the specific HMO or HMO blend studied, the growing body of evidence supports the role of HMOs in shaping the infant gut microbiome and contributing to early immune development.
• How are HMOs, the microbiome, and immune function connected?
  HMOs help shape the gut microbiome by selectively supporting beneficial bacteria, including Bifidobacterium, that produce metabolites involved in host physiology. Emerging evidence suggests that microbiome-derived metabolites, such as short-chain fatty acids and secondary bile acids, may interact with immune pathways and contribute to immune signaling both within and beyond the gastrointestinal tract. This growing body of research highlights the interconnected relationship among nutrition, gut microbes, microbial metabolites, and immune development during infancy.